0001104659-14-085930.txt : 20141210 0001104659-14-085930.hdr.sgml : 20141210 20141210152930 ACCESSION NUMBER: 0001104659-14-085930 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141208 FILED AS OF DATE: 20141210 DATE AS OF CHANGE: 20141210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Selisker Rachel R CENTRAL INDEX KEY: 0001313793 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 141277903 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE STREET 2: 3RD FLOOR CITY: BEDMINSTER STATE: NJ ZIP: 07921 4 1 a4.xml 4 X0306 4 2014-12-08 0 0000890465 NPS PHARMACEUTICALS INC NPSP 0001313793 Selisker Rachel R 550 HILLS DRIVE BEDMINSTER NJ 07921 1 0 0 0 Common Stock 2014-12-08 4 M 0 23157 4.24 A 33057 D Common Stock 2014-12-08 4 S 0 23157 34.5028 D 9900 D Stock Options (right to buy) 4.24 2014-12-08 4 M 0 23157 0 D 2019-09-23 Common Stock 23157 1208 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.50 to $34.53, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. On September 23, 2009, the reporting person received a grant of 36,000 stock options under the Issuer's 2005 Omnibus Incentive Plan. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first anniversary of the date of grant and 6.25% every three months thereafter. As of the date of this filing, all 36,000 stock options have vested. /s/ Rachel Selisker, by Christine Mikail as attorney in fact 2014-12-10